Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care.
A $500,000 grant from the Pancreatic Cancer Action Network will help a Rutgers Cancer Institute of New Jersey physician-scientist explore a biological event associated with a signaling pathway known as Netrin-1 that enables cancer cells to live.
The Hugs for Brady Foundation has announced a $500,000 pledge to Rutgers Cancer Institute of New Jersey to support a dedicated laboratory space for pediatric cancer research.
Rutgers Cancer Institute of New Jersey Director Steven K. Libutti, MD, FACS, who is also senior vice president of oncology services at RWJBarnabas Health and vice chancellor for cancer programs for Rutgers Biomedical and Health Sciences, has been named by the business journal NJBIZ to its Power 100 list.
With spring now here, home improvement projects are on many ‘to do’ lists. With that come the usual warnings about safe removal of construction and home materials made of asbestos in much older homes, as exposure to this fibrous mineral is a known risk factor to the development of mesothelioma. A Rutgers Cancer Institute expert shares more about this type of cancer.
Research by Rutgers Cancer Institute of New Jersey investigators explores the use of a diabetes drug and its impact on pancreatic cancer and finds that targeting a certain signaling pathway with this agent may be a novel strategy for the prevention and treatment of metastatic pancreatic cancer.
There’s more to caring for cancer patients than treatments and doctor’s visits. At Rutgers Cancer Institute of New Jersey the Social Work Department is dedicated to treating the ‘whole’ patient by helping them navigate important issues one may not think about in connection with the cancer journey.
With colorectal cancer tabbed as the third leading cause of cancer death among both men and women in the nation, experts from Rutgers Cancer Institute discuss the benefits of screening.
While cancer treatment advances are being made in precision medicine and immunotherapy, a unique combination of traditional therapies can also provide some patients benefit. A Rutgers Cancer Institute of New Jersey expert shares more about an approach combining cytoreductive surgery and hyperthermic chemotherapy for cancers that have spread to the abdominal cavity.
Rutgers Cancer Institute of New Jersey is now recognized as a Center of Excellence by the Myelodysplastic Syndromes (MDS) Foundation in the research, diagnosis and treatment of MDS disorders.
Rutgers Cancer Institute of New Jersey research further elucidates a tumor suppression mechanism behind the human Parkin gene – which could help inform treatment decisions for breast cancer patients who have a Parkin mutation or loss of Parkin expression.
A number of chief physicians at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, are being honored as a ‘Jersey Choice Top Doctor’ by New Jersey Monthly magazine.
Research by Rutgers Cancer Institute of New Jersey investigators and others shows that the architecture of a cell’s nucleus influences the type and frequency of mutations in cancer genomes beyond the effects already captured by DNA packaging and ordering.
Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer carries mutations in the p53 gene.